{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:34:56Z","timestamp":1790573696142,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:00:00Z","timestamp":1381881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Insulin\u2010like growth factor (IGF) and adipokines have been implicated in prostate cancer carcinogenesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHOD<\/jats:title><jats:p>Data from 122 men with serum samples drawn within 3 months of starting ADT for metastatic prostate cancer was accessed retrospectively. IGF\u20101, IGF binding protein (BP)\u20101, leptin, and adiponectin levels were measured by multiplex electrochemiluminescence assays. A multivariable Cox model assessed the association of time to castration resistant prostate cancer (CRPC) and overall survival by the protein levels, adjusted for clinical variables, age and prostate specific antigen (PSA) levels at start of ADT, race, ECOG status, extent of metastases and were reported as hazard ratio (HR) with 95% confidence interval (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Median follow\u2010up and overall survival were 44 and 42.2 months, respectively. ECOG performance status (\u22651 vs. 0) was negatively associated with overall survival [HR\u2009=\u20092.8 (1.1\u20137.0),<jats:italic>P<\/jats:italic>\u2009=\u20090.03], and PSA nadir &lt;0.2 was predictive of longer time to CRPC [HR\u2009=\u20090.3 (0.2\u20130.5),<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001]. The median time to CRPC by low, middle, and top IGFBP\u20101 tertile distribution was 20.7, 18.1, and 12.4 months, respectively, with HR for middle versus low tertile levels 3.1 (1.7\u20135),<jats:italic>P<\/jats:italic>\u2009=\u20090.0003, and for top versus low tertile levels was 2.4 (1.3\u20134.2),<jats:italic>P<\/jats:italic>\u2009=\u20090.003. The median overall survival by low, middle and top tertile IGFBP\u20101 level was 48.5, 46.4, and 32.8 months, respectively, with HR for top versus low tertile 2.5 (1.2\u20135.1),<jats:italic>P<\/jats:italic>\u2009=\u20090.01. There was no association with IGF\u20101, adiponectin and leptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Elevated IGFBP\u20101 appears to be associated with shorter time to CRPC and lower overall survival in men with metastatic prostate cancer.<jats:italic>Prostate 74:225\u2013234, 2014<\/jats:italic>. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.22744","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T14:26:05Z","timestamp":1381933565000},"page":"225-234","source":"Crossref","is-referenced-by-count":32,"title":["Elevated insulin\u2010like growth factor binding protein\u20101 (IGFBP\u20101) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival"],"prefix":"10.1002","volume":"74","author":[{"given":"Jaya","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Medicine Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn P.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute Boston Massachusetts"},{"name":"Harvard School of Public Health Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Evan","sequence":"additional","affiliation":[{"name":"Department of Medicine Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nakabayashi","sequence":"additional","affiliation":[{"name":"Department of Medicine Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Fichorova","sequence":"additional","affiliation":[{"name":"Department of Medicine Brigham and Women's Hospital Boston Massachusetts"},{"name":"Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rider","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health Boston Massachusetts"},{"name":"Department of Medicine Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorelei","family":"Mucci","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[{"name":"Department of Medicine Dana\u2010Farber Cancer Institute Boston Massachusetts"},{"name":"Harvard Medical School Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Department of Medicine Dana\u2010Farber Cancer Institute Boston Massachusetts"},{"name":"Harvard Medical School Boston Massachusetts"},{"name":"Hoosier Oncology Group Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09408-4"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70063-8"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92163-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23440"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.5226"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1055-9965.1646.13.10","article-title":"Metabolic syndrome and the risk of prostate cancer in Finnish men: A population\u2010based study","volume":"13","author":"Laukkanen JA","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj284"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.08.018"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.919"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.12.911"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-7-200810070-00006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24202"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3455"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26980-0_4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0082"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2005.00562.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304984200"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.12.053"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/01635580802419798"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq443"},{"key":"e_1_2_6_24_1","article-title":"Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"30","author":"Rudman SMGK","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac702628q"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc B"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.22.1965"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21125"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.563"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.10.003"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20929"},{"key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1210\/jcem.82.7.4070","article-title":"Free insulin\u2010like growth factor I (IGF\u2010I) in healthy subjects: Relationship with IGF\u2010binding proteins and insulin sensitivity","volume":"82","author":"Nyomba BL","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.22.10553"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-11-0240"},{"key":"e_1_2_6_36_1","first-page":"3575","article-title":"Castration\u2010induced increases in insulin\u2010like growth factor\u2010binding protein 2 promotes proliferation of androgen\u2010independent human prostate LNCaP tumors","volume":"63","author":"Kiyama S","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.127"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.015"},{"key":"e_1_2_6_39_1","first-page":"3058","article-title":"Castration\u2010induced up\u2010regulation of insulin\u2010like growth factor binding protein\u20105 potentiates insulin\u2010like growth factor\u2010I activity and accelerates progression to androgen independence in prostate cancer models","volume":"60","author":"Miyake H","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20655"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1016-x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1627"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1245"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9407-y"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22744","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.22744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T18:34:58Z","timestamp":1716057298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.22744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,16]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/pros.22744"],"URL":"https:\/\/doi.org\/10.1002\/pros.22744","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,16]]}}}